Aura Biosciences Statistics
Total Valuation
AURA has a market cap or net worth of $819.27 million. The enterprise value is $512.02 million.
| Market Cap | 819.27M |
| Enterprise Value | 512.02M |
Important Dates
The last earnings date was Tuesday, August 11, 2026, before market open.
| Earnings Date | Aug 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AURA has 103.70 million shares outstanding. The number of shares has increased by 42.27% in one year.
| Current Share Class | 103.70M |
| Shares Outstanding | 103.70M |
| Shares Change (YoY) | +42.27% |
| Shares Change (QoQ) | +40.65% |
| Owned by Insiders (%) | 1.18% |
| Owned by Institutions (%) | 71.24% |
| Float | 79.92M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.59 |
| P/TBV Ratio | 2.60 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 16.82, with a Debt / Equity ratio of 0.05.
| Current Ratio | 16.82 |
| Quick Ratio | 16.65 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -53.49% and return on invested capital (ROIC) is -32.90%.
| Return on Equity (ROE) | -53.49% |
| Return on Assets (ROA) | -31.24% |
| Return on Invested Capital (ROIC) | -32.90% |
| Return on Capital Employed (ROCE) | -42.02% |
| Weighted Average Cost of Capital (WACC) | 6.30% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.16M |
| Employee Count | 113 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, AURA has paid $81,000 in taxes.
| Income Tax | 81,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +20.61% in the last 52 weeks. The beta is 0.40, so AURA's price volatility has been lower than the market average.
| Beta (5Y) | 0.40 |
| 52-Week Price Change | +20.61% |
| 50-Day Moving Average | 7.17 |
| 200-Day Moving Average | 6.51 |
| Relative Strength Index (RSI) | 58.45 |
| Average Volume (20 Days) | 770,079 |
Short Selling Information
The latest short interest is 6.36 million, so 6.13% of the outstanding shares have been sold short.
| Short Interest | 6.36M |
| Short Previous Month | 5.61M |
| Short % of Shares Out | 6.13% |
| Short % of Float | 7.96% |
| Short Ratio (days to cover) | 11.73 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -138.08M |
| Pretax Income | -130.93M |
| Net Income | -131.01M |
| EBITDA | -136.99M |
| EBIT | -138.08M |
| Earnings Per Share (EPS) | -$1.77 |
Balance Sheet
The company has $323.84 million in cash and $16.59 million in debt, with a net cash position of $307.25 million or $2.96 per share.
| Cash & Cash Equivalents | 323.84M |
| Total Debt | 16.59M |
| Net Cash | 307.25M |
| Net Cash Per Share | $2.96 |
| Equity (Book Value) | 315.27M |
| Book Value Per Share | 3.05 |
| Working Capital | 309.47M |
Cash Flow
In the last 12 months, operating cash flow was -$103.01 million and capital expenditures -$344,000, giving a free cash flow of -$103.35 million.
| Operating Cash Flow | -103.01M |
| Capital Expenditures | -344,000 |
| Depreciation & Amortization | 1.09M |
| Net Borrowing | n/a |
| Free Cash Flow | -103.35M |
| FCF Per Share | -$1.00 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AURA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -42.27% |
| Shareholder Yield | -42.27% |
| Earnings Yield | -15.99% |
| FCF Yield | -12.62% |
Analyst Forecast
The average price target for AURA is $16.60, which is 110.13% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $16.60 |
| Price Target Difference | 110.13% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |